VALN logo

VALN Valneva SE

NASDAQ Global Select · Biotechnology · Healthcare

$5.16
-0.20 (-3.82%)

Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-p…

Market Cap: $490.86Mvalneva.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
53
4 mentions
—
60d
49
7 mentions
—
90d
49
7 mentions
—
news: 7

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 1Strong Sell 0
Avg price target$11+113.2%
Low $11Median $11High $11
Current Consensus

Revenue

$35.52M+93.07%
$10.94M$100.04M$189.14M$278.24M
Sep 2016Jun 2026

Analyst Estimates

FY2025
$-0.98
$-1.15–$-0.86
1 analysts
FY2026
$-0.92
$-1.09–$-0.76
1 analysts
FY2027
$0.57
$-1.19–$2.33
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Thomas Lingelbach
Sector
Healthcare
Industry
Biotechnology
Employees
674
Beta
1.36
Country
FR
Piotroski score
1 / 9 (Weak)
Altman Z-score
-2.04
valneva.com